Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Ly

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 14, 2015
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitorsHuiyong Hu, Xiaojing Wang, Grace Ka Yan Chan, et al.
Clinical and Translational Science|June 23, 2023
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteersFei Tang, Rebecca Kunder, Tom Chu, et al.
Neoplasia (New York, N.Y.)|January 10, 2014
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.
Cancer Research|August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate CancerLingyan Jin, Jesse Garcia, Emily Chan, et al.
Journal of Medicinal Chemistry|April 27, 2017
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized BioavailabilityXiaojing Wang, Aleksandr Kolesnikov, Suzanne Tay, et al.
Npj Drug Discovery|June 30, 2026
Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegenerationRebecca R Leahey, Martin Weber, Chang Hoon Cho, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2017
Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300Kwong Wah Lai, F Anthony Romero, Vickie Tsui, et al.
Journal of Neuropathology and Experimental Neurology|June 6, 2025
Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transectionSeong Kwon Hur, Rebecca R Leahey, Mitchell Geringer, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Optimization of Brain Penetrant SARM1 Orthosteric Inhibitors and Discovery of Their Paradoxical Subinhibitory ActivationSamantha A Green, Russell T Smith, Jessica M Grandner, et al.
Journal of Medicinal Chemistry|November 21, 2017
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) InhibitorsSarah M Bronner, Jeremy Murray, F Anthony Romero, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|October 14, 2015
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitorsHuiyong Hu, Xiaojing Wang, Grace Ka Yan Chan, et al.
Clinical and Translational Science|June 23, 2023
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteersFei Tang, Rebecca Kunder, Tom Chu, et al.
Neoplasia (New York, N.Y.)|January 10, 2014
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.
Cancer Research|August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate CancerLingyan Jin, Jesse Garcia, Emily Chan, et al.
Journal of Medicinal Chemistry|April 27, 2017
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized BioavailabilityXiaojing Wang, Aleksandr Kolesnikov, Suzanne Tay, et al.
Npj Drug Discovery|June 30, 2026
Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegenerationRebecca R Leahey, Martin Weber, Chang Hoon Cho, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2017
Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300Kwong Wah Lai, F Anthony Romero, Vickie Tsui, et al.
Journal of Neuropathology and Experimental Neurology|June 6, 2025
Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transectionSeong Kwon Hur, Rebecca R Leahey, Mitchell Geringer, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Optimization of Brain Penetrant SARM1 Orthosteric Inhibitors and Discovery of Their Paradoxical Subinhibitory ActivationSamantha A Green, Russell T Smith, Jessica M Grandner, et al.
Journal of Medicinal Chemistry|November 21, 2017
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) InhibitorsSarah M Bronner, Jeremy Murray, F Anthony Romero, et al.
Pageof 4